


Harm reduction:

Diagnosis & Treatment of Opioid Use Disorder Including MAT,
Naloxone Prescribing, Risks of Co-Prescribing Benzos

Harm Reduction Includes:

- ▶ avoiding co-prescribing of opioids and benzodiazepines
- ▶ prescribing naloxone
- ▶ recognizing and treating opioid use disorder



Age-adjusted death rates for drug poisoning per 100,000 population, maps from national center for health statistics at the CDC.

1.5x more US residents live with a substance use disorder than all cancers combined

35% of primary care patients on opioids for chronic pain met DSM-V criteria for OUD-opioid use disorder

3-26% of primary care patients on opioids for chronic pain met DSM-IV criteria for OUD

Higher daily dose & longer treatments courses increased risk for OUD

75% of heroin users started with prescription opioids

But **only 4%** of *nonmedical* prescription opioid users initiated heroin use

Cicero, JAMA Psychiatry 2014;71:821-6; Muhuri, CBHSQ Data Review 2013; MMWR 2015;64:719-25; Boscarino, J Add Dis 2011;30:185-194; 2016 CDC Guidelines, p.32.

NALOXONE SHOULD BE PRESCRIBED FOR:

- 1 all patients on chronic opioids
- 2 anyone at risk for experiencing or witnessing an overdose

Learn more at:
mainemed.com/MICIS

Misconceptions Regarding Opioids and Addiction


- Addiction is the same as physical dependence and tolerance.
- Pain protects patients from addiction to opioid medications.
- Only long-term use of certain opioids produces addiction.
- Addiction is simply a set of bad choices.
- Only patients with certain characteristics are vulnerable to addiction.
- Medication-assisted therapies are just substitutes for heroin or opioids.

Adapted from: Volkow, NEJM 2016;374(13):1254. Used by permission.

2016 CDC Recommendations

- Avoid concurrent opioid and benzodiazepine prescribing
- Offer treatment for opioid use disorder

Improving Opioid Prescribing and Patient Safety: Educational Outreach



Disclaimer

These are general recommendations only; specific clinical decisions should be made by the treating healthcare provider based on an individual patient's clinical condition. This document presents only general information regarding prescribing laws in the state of Maine. Prescribers in Maine are instructed to independently study Chapter 488 and comply with current state law and rules.

Learning Objectives

- ▶ Understand benefits of buprenorphine prescribing
- ▶ Anticipate prescribing naloxone for all patients and families at risk

Additional Resources

- ▶ 2016 CDC Opioid Prescribing Guidelines: www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm
- ▶ Agency Medical Directors' Group, Washington State, 2015 Opioid Prescribing Guideline summary and MME calculator: www.agencymeddirectors.wa.gov
- ▶ Caring for ME: a joint project of Maine Quality Counts and the Maine Medical Association: qclearninglab.org/welcome-caring-for-me/
- ▶ Quality Counts Controlled Medication Playbook: mainequalitycounts.org/what-we-do/population-health/chronic-pain-and-controlled-medication-playbook/
- ▶ Opioid and Chronic Pain Toolkit available at MICISMaine.org

Funding Statement/Disclosure

This material was compiled by Elisabeth Fowlie Mock, MD, MPH, FAAFP, academic detailer for the Maine Independent Clinical Information Service (MICIS). Dr. Mock works as an Adult Hospitalist at Eastern Maine Medical Center.

MICIS is administered by the Maine Medical Association with funding from the Office of MaineCare Services, Maine DHHS. MICIS does not accept any compensation from any pharmaceutical company. Not all medications referenced in this document have FDA indications for the treatment of various chronic pain conditions ('off-label use disclosure').

Education Statement

This monograph was created in support of accompanying live educational activities. This monograph is not approved for medical education credit.

FMI:

Maine Independent Clinical Information Service (MICIS) c/o Maine Medical Association, MICISMaine.org, 207.622.3374